Research progress on early stage extranodal natural killer/T cell lymphoma
Xu Tian1,2, Yin Li1, Zhan Mengna1, Hu Xinyu1, Xue Ke1, Pei Shuai3, He Xia1,2,3
1Affiliated Cancer Hospital of Nanjing Medical University & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research,Nanjing 210009,China; 2Fourth School of Clinical Medicine,Nanjing Medical University,Nanjing 210000,China; 3Xuzhou Medical University,Xuzhou 221000,China
Abstract：Extranodal natural killer/T-cell lymphoma (ENKTCL) is the subtype of non-Hodgkin lymphoma with high heterogeneity and invasiveness. Though most ENKTCL patients are present as early-stage at diagnosis, clinical prognosis significantly differs due to the limitations of clinical staging. Radiotherapy (RT) and chemotherapy (CT) are the first-line treatments for early ENKTCL patients. However, there is no consensus on the combined modalities of RT and CT, and their optimal strategy. With the continuous renewal of clinical staging and prognostic models, early-stage ENKTCL patients tend to accept risk-adapted treatment with proper stratification. In this review, the latest research progresses on clinical staging, prognostic models and treatment were retrospectively analyzed, aiming to provide references for clinical decision-making.
Xu Tian,Yin Li,Zhan Mengna et al. Research progress on early stage extranodal natural killer/T cell lymphoma[J]. Chinese Journal of Radiation Oncology, 2021, 30(6): 631-636.
[1] Wang L, Li LR, Zhang L, et al. The landscape of new drugs in extranodal NK/T-cell lymphoma[J]. Cancer Treat Rev, 2020, 89:102065. DOI:10.1016/j.ctrv.2020.102065. [2] Niu SQ, Yang Y, Li YY, et al. Primary site and regional lymph node involvement are independent prognostic factors for early-stage extranodal nasal-type natural killer/T cell lymphoma[J]. Chin J Cancer, 2016, 35(5):255-263.DOI:10.1186/s40880-016-0096-0. [3] Tse E, Kwong YL. The diagnosis and management of NK/T-cell lymphomas[J]. J Hematol Oncol, 2017, 10(1):85-97.DOI:10.1186/s13045-017-0452-9. [4] Wang L, Xia ZJ, Huang HQ, et al. Cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in the treatment of stage Ⅰ e/ⅡE extranodal natural killer/T cell lymphoma, nasal type:13-year follow-up in 135 patients[J]. Int J Hematol, 2012, 96(5):617-623.DOI:10.1007/s12185-012-1174-y. [5] Yang Y, Zhu Y, Cao JZ, et al. Risk-adapted therapy for early-stage extranodal nasal-type NK/T-cell lymphoma:analysis from a multicenter study[J]. Blood, 2015, 126(12):1424-1432. DOI:10.1182/blood-2015-04-639336. [6] Yang Y, Zhang YJ, Zhu Y, et al. Prognostic nomogram for overall survival in previously untreated patients with extranodal NK/T-cell lymphoma, nasal-type:a multicenter study[J]. Leukemia, 2015, 29(7):1571-1577.DOI:10.1038/leu.2015.44. [7] Chen SY, Yang Y, Qi SN, et al. Validation of nomogram-revised risk index and comparison with other models for extranodal nasal-type NK/T-cell lymphoma in the modern chemotherapy era:indication for prognostication and clinical decision-making[J]. Leukemia, 2021, 35(1):130-142. DOI:10.1038/s41375-020-0791-3. [8] Yan Z, Huang HQ, Wang XX, et al. A TNM staging system for nasal NK/T-cell lymphoma[J]. PLoS One, 2015, 10(6):e0130984.DOI:10.1371/journal.pone.0130984. [9] Hong H, Li Y, Lim ST, et al. A proposal for a new staging system for extranodal natural killer T-cell lymphoma:a multicenter study from China and Asia lymphoma study group[J]. Leukemia, 2020, 34(8):2243-2248. DOI:10.1038/s41375-020-0740-1. [10] Lee J, Suh C, Park YH, et al. Extranodal natural killer T-cell lymphoma, nasal-type:a prognostic model from a retrospective multicenter study[J]. J Clin Oncol, 2006, 24(4):612-618. DOI:10.1200/JCO.2005.04.1384. [11] Kim SJ, Yoon DH, Jaccard A, et al. A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment:a multicentre, retrospective analysis[J]. Lancet Oncol, 2016, 17(3):389-400.DOI:10.1016/S1470-2045(15)00533-1. [12] Wang ZY, Liu QF, Wang H, et al. Clinical implications of plasma Epstein-Barr virus DNA in early-stage extranodal nasal-type NK/T-cell lymphoma patients receiving primary radiotherapy[J]. Blood, 2012, 120(10):2003-2010.DOI:10.1182/blood-2012-06-435024. [13] Qi SN, Yang Y, Zhang YJ, et al. Risk-based, response-adapted therapy for early-stage extranodal nasal-type NK/T-cell lymphoma in the modern chemotherapy era:a China lymphoma collaborative group study[J]. Am J Hematol, 2020, 95(9):1047-1056.DOI:10.1002/ajh.25878. [14] Pak K, Kim BS, Kim K, et al. Prognostic significance of standardized uptake value on F18-FDG PET/CT in patients with extranodal nasal type NK/T cell lymphoma:a multicenter, retrospective analysis[J]. Am J Otolaryngol, 2018, 39(1):1-5. DOI:10.1016/j.amjoto.2017.10.009. [15] Xiong J, Cui BW, Wang N, et al. Genomic and transcriptomic characterization of natural killer t cell lymphoma[J]. Cancer Cell, 2020, 37(3):403-419. DOI:10.1016/j.ccell.2020.02.005. [16] Liu QF, Wang WH, Wang SL, et al. Immunophenotypic and clinical differences between the nasal and extranasal subtypes of upper aerodigestive tract natural killer/T-cell lymphoma[J]. Int J Radiat Oncol Biol Phys, 2014, 88(4):806-813.DOI:10.1016/j.ijrobp.2013.12.005. [17] Campo E, Swerdlow SH, Harris NL, et al. The 2008 WHO classification of lymphoid neoplasms and beyond:evolving concepts and practical applications[J]. Blood, 2011, 117(19):5019-5032. DOI:10.1182/blood-2011-01-293050. [18] Wu T, Yang Y, Zhu SY, et al. Risk-adapted survival benefit of IMRT in early-stage NKTCL:a multicenter study from the China lymphoma collaborative group[J]. Blood Adv, 2018, 2(18):2369-2377.DOI:10.1182/bloodadvances.2018021311. [19] Shen Q, Ma X, Hu W, et al. Intensity-modulated radiotherapy versus three-dimensional conformal radiotherapy for stage Ⅰ-Ⅱ natural killer/T-cell lymphoma nasal type:dosimetric and clinical results[J]. Radiat Oncol, 2013, 8(1):152-159. DOI:10.1186/1748-717X-8-152. [20] Yamaguchi M, Suzuki R, Oguchi M. Advances in the treatment of extranodal NK/T-cell lymphoma, nasal type[J]. Blood, 2018,131(23):2528-2540.DOI:10.1182/blood-2017-12-791418. [21] Yahalom J, Illidge T, Specht L, et al. Modern radiation therapy for extranodal lymphomas:field and dose guidelines from the International Lymphoma Radiation Oncology Group[J]. Int J Radiat Oncol Biol Phys, 2015, 92(1):11-31.DOI:10.1016/j.ijrobp.2015.01.009. [22] Yang Y, Cao JZ, La SM, et al. Association of improved locoregional control with prolonged survival in early-stage extranodal nasal-type natural killer/t-cell lymphoma[J]. JAMA Oncol, 2017, 3(1):83-91.DOI:10.1001/jamaoncol.2016.5094. [23] Qi SN, Yang Y, Song YQ, et al. First-line non-anthracycline-based chemotherapy for extranodal nasal-type NK/T-cell lymphoma:a retrospective analysis from the CLCG[J]. Blood Adv, 2020, 4(13):3141-3153.DOI:10.1182/bloodadvances.2020001852. [24] Qi SN, Xu LM, Yuan ZY, et al. Effect of primary tumor invasion on treatment and survival in extranodal nasal-type NK/T-cell lymphoma in the modern chemotherapy era:a multicenter study from the China Lymphoma Collaborative Group (CLCG)[J]. Leuk Lymphoma, 2019, 60(11):2669-2678. DOI:10.1080/10428194.2019.1602265. [25] Huang MJ, Jiang Y, Liu WP, et al. Early or up-front radiotherapy improved survival of localized extranodal NK/T-cell lymphoma, nasal-type in the upper aerodigestive tract[J]. Int J Radiat Oncol Biol Phys, 2008, 70(1):166-174.DOI:10.1016/j.ijrobp.2007.05.073. [26] Zang J, Li C, Luo SQ, et al. Early radiotherapy has an essential role for improving survival in patients with stage Ⅰ-Ⅱ nasal-type of NK/T cell lymphoma treated with L-asparaginase-containing chemotherapy—a single institution experience[J]. Ann Hematol, 2015, 94(4):583-591.DOI:10.1007/s00277-014-2244-4. [27] Hu S, Zhou D, Zhang W. The optimal timing of radiotherapy in the combined modality therapy for limited-stage extranodal NK/T cell lymphoma (ENKTL):a systematic review and meta-analysis[J]. Ann Hematol, 2018, 97(12):2279-2287.DOI:10.1007/s00277-018-3479-2. [28] Tsai HJ, Lin SF, Chen CC, et al. Long-term results of a phase Ⅱ trial with frontline concurrent chemoradiotherapy followed by consolidation chemotherapy for localized nasal natural killer/T-cell lymphoma[J]. Eur J Haematol, 2015, 94(2):130-137.DOI:10.1111/ejh.12405. [29] Moon JH, Lee BH, Kim JA, et al. Clinical impact of induction treatment modalities and optimal timing of radiotherapy for the treatment of limited-stage NK/T cell lymphoma[J]. Leuk Res,2016,49:80-87.DOI:10.1016/j.leukres.2016.08.015. [30] Kwong YL, Kim SJ, Tse E, et al. Sequential chemotherapy/radiotherapy was comparable with concurrent chemoradiotherapy for stage Ⅰ/Ⅱ NK/T-cell lymphoma[J]. Ann Oncol, 2018, 29(1):256-263.DOI:10.1093/annonc/mdx684. [31] Qian M, Tao H, Xu W, et al. A systematic comparison of treatment modalities for nasal extranodal natural killer/T-cell lymphoma in early stages between concurrent chemoradiotherapy and sequential chemotherapy[J]. Oncol Targets Ther, 2017, 10:3617-3623.DOI:10.2147/OTT. S136386. [32] Li J, Li Y, Zhong M, et al. A multicenter retrospective comparison of sequential versus sandwich chemoradiotherapy for stage Ⅰ e-ⅡE extranodal natural killer/T-Cell lymphoma, nasal type[J]. J Cancer, 2018, 9(9):1598-1606.DOI:10.7150/jca.24310. [33] Wang L, Wang ZH, Chen XQ, et al. First-line combination of GELOX followed by radiation therapy for patients with stage Ⅰ e/ⅡE ENKTL:an updated analysis with long-term follow-up[J]. Oncol Lett, 2015, 10(2):1036-1040.DOI:10.3892/ol.2015.3327.
2021, Vol. 30 
